SK Biopharmaceuticals pauses KRAS G12D inhibitor development
AI Summary- SK Biopharmaceuticals paused follow-up development of its KRAS G12D inhibitor.
- The compound produced dose-dependent tumor suppression without significant weight loss in pancreatic cancer animal models.
- SK Biopharmaceuticals is prioritizing radiopharmaceutical research and development after establishing an RPT organization late last year.